Advanced management of heart block

2. Jens Martensson
PUBLISHED BY GIANLUCA MASSARO
PUBLISHED IN EMJ INTERVENTIONAL
CARDIOLOGY
PUBLISHED ON OCTOBER 3, 2022
‘Leave Nothing Behind’ Strategy in
Coronary and Peripheral Artery Disease:
An Insight into Sirolimus-Coated Balloons

3. Jens Martensson

4. Jens Martensson

5. Jens Martensson
Plain old balloon angioplasty (POBA) paved the way for
percutaneous coronary treatment. Subsequently, coronary stents
were initially introduced as a bailout strategy for complications
associated with POBA (mainly acute recoil and flow-limiting
dissection), and dual antiplatelet therapy represents the gold
standard in treating coronary artery disease to the present day.
Drug-eluting stents (DES) have shown to be more effective in
the prevention of restenosis and repeated revascularisation than
bare metal stents

6. Jens Martensson
• To understand how to widen the use of a sirolimus DCB in new ad
challenging treatment
• To know why sirolimus coated ballon is the ideal choice in native
vessel disease treatment through this case presentation
LEARNING OBJECTIVES

7. Jens Martensson

8. Jens Martensson
Currently, the use of DCB is indicated primarily in the treatment of ISR and
atherosclerosis of small-calibre native vessels . Acute coronary syndromes,
bifurcation lesions, and stenosis in medium-to-large calibre vessels represent
new frontiers in the use of DCB.
SIROLIMUS-COATED BALLOONS IN
CORONARY ARTERY DISEASE

9. Jens Martensson
How dos it works
Conversion of sirolimus
drug into sub micron sized
particles

10. Jens Martensson

11. Jens Martensson
• Encapsulation of sub
micron sized sirolimus drug
into highly bicompatible
drug carrier-
PHOSPHOLIPID

12. Jens Martensson
• Upon inflation of SCB at
target site ,dug carrier with
sirolimus drug inside gets
transferred to the vessels
wall following the principle
of co efficient diffusion

13. Jens Martensson
• Upon body pH variation
drug carrier mimics the
body lipid and liberates
sirolimus

14. Jens Martensson
• The sub micron sized
sirolimus drug particle
penetrate the deepest layer
of the vessels over a period

15. Jens Martensson
• Facilitate better adhesion of sirolimus on the balloon
surface
• Effective drug transfer to the deepest layer of the vessel
• Better in tissue bio availability of sirolimus
ADVANTAGE OF SIROLMIUS

16. Jens Martensson
• DCB is the unique formation of sirolimus encapsulated into a
phospholipid drug carrier
• Drug levels of sirolimus are sustained out to 30-6- days in animal
models
• Successful evidence of drug effect without long term toxicity
• Minimal embolic debris are seen in downstream beds
CONCLUSION

17. Jens Martensson
• This system meets the requirements of the a safe and
efficacious drug coated balloon and represent an
important advance In coronary and peripheral
percutaneous intervention

18. Jens Martensson
Questions ?

19. Jens Martensson
Thank you